BioMarin Pharmaceutical Yönetim
Yönetim kriter kontrolleri 1/4
BioMarin Pharmaceutical CEO'su Alexander Hardy, Dec2023 tarihinde atandı, in görev süresi 2.42 yıldır. in toplam yıllık tazminatı $ 21.93M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5.2% maaş ve 94.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.11% ine doğrudan sahiptir ve bu hisseler $ 11.57M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 2.4 yıldır.
Anahtar bilgiler
Alexander Hardy
İcra Kurulu Başkanı
US$21.9m
Toplam tazminat
| CEO maaş yüzdesi | 5.16% |
| CEO görev süresi | 2.4yrs |
| CEO sahipliği | 0.1% |
| Yönetim ortalama görev süresi | 2.4yrs |
| Yönetim Kurulu ortalama görev süresi | 2.4yrs |
Son yönetim güncellemeleri
Recent updates
BMRN: Fair Value View Weighs Voxzogo Headwinds Against Amicus Acquisition Potential
Analysts have trimmed their average price target on BioMarin Pharmaceutical slightly, cutting fair value by about $0.30 to $55.36. They are factoring in a higher discount rate, modestly stronger long term growth and margins, and a slightly lower future P/E multiple following recent reassessments of the Voxzogo franchise and the planned Amicus acquisition.BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
Apr 15BMRN: Fair Value View Balances Voxzogo Risks And Amicus Opportunity
The analyst fair value estimate for BioMarin Pharmaceutical has been trimmed from about $60 to roughly $55.66 as analysts factor in a higher discount rate, a lower future P/E multiple, and mixed expectations around Voxzogo and the Amicus acquisition. Analyst Commentary Recent research on BioMarin reflects a mixed but generally constructive stance, with several firms revising price targets while keeping positive ratings.
BMRN: Pending Amicus Deal Will Reshape Earnings Power Despite Treatment Franchise Risks
Analyst revisions point to a slightly lower blended fair value for BioMarin Pharmaceutical, trimming the price target by about $0.09 as analysts factor in mixed views on Voxzogo and the pending Amicus deal while keeping underlying growth, margin, and P/E assumptions broadly unchanged. Analyst Commentary Recent Street research reflects a split view on BioMarin, with most analysts still constructive on long term value creation while others focus on Voxzogo related risks and competitive pressures.BMRN: Amicus Acquisition Is Expected To Reshape Future Earnings Power
Analysts have nudged their fair value estimate for BioMarin to $88.96 from $88.65, citing updates to revenue growth, profit margin and future P/E assumptions as they reassess Voxzogo risks, competitive pressure and the potential impact of the Amicus acquisition. Analyst Commentary Recent street research paints a mixed picture for BioMarin, with analysts recalibrating expectations around Voxzogo, the Amicus acquisition and the broader rare disease portfolio.
BMRN: Rare Disease Portfolio Expansion And Amicus Acquisition Will Drive Repricing
Our BioMarin Pharmaceutical update trims the fair value estimate slightly to $120 from $122, as analysts weigh higher long term growth and margin assumptions against a higher discount rate and a lower future P/E multiple. Recent Street price target moves now cluster in the mid to high $90s, with outliers as low as $55 and as high as $105.BMRN: Recent Coverage Shifts Will Support Higher Future Earnings Multiple
Analysts have trimmed their fair value estimate for BioMarin Pharmaceutical by roughly $2 to about $88.65. This reflects updated views on discount rates, revenue growth, profit margins, and future P/E assumptions drawn from recent Street research.BMRN: Shares Should Recover As Fresh Coverage Supports Higher Future Earnings Multiple
Analysts have lifted their price target for BioMarin Pharmaceutical by about US$1 to roughly US$91, citing updated assumptions around revenue growth, margins and a higher future P/E multiple, supported by recent positive Street research coverage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Street coverage as support for using a higher future P/E multiple, which feeds directly into a slightly higher fair value range around US$91.BMRN: Reset Long Term Outlook Will Shape Risk Balance Going Forward
Analysts have reduced their price target on BioMarin Pharmaceutical to US$60 from US$67.39 as they factor in updated long term revenue scenarios, a higher discount rate, and slightly stronger margin assumptions following recent quarterly results and guidance changes. Analyst Commentary Recent Street research shows a cluster of price target cuts on BioMarin, generally following an "okay" Q3 print, a Q3 revenue miss in some areas, and updated long term guidance that now reflects a wider range of possible competitive and intellectual property outcomes.BMRN: Shares Should Recover As 2027 Revenue Reset Clarifies Competition Risk
Analysts now see fair value for BioMarin Pharmaceutical at $89.74 per share, a small move up that reflects lower long term revenue growth assumptions, a slightly higher profit margin outlook, and modestly higher future P/E expectations following recent price target cuts tied to Voxzogo trends, revised 2027 revenue guidance, and potential competition. Analyst Commentary Recent Street research shows a wide range of views on BioMarin, with a clear focus on Voxzogo trends, updated 2027 revenue scenarios, and the impact of potential competition on execution and valuation.BMRN: Shares Will Strengthen As 2025 Guidance Reset Supports Future Upside
Analysts have trimmed their average price target on BioMarin Pharmaceutical by roughly $1 to reflect a modest reset in long term revenue and margin expectations after Q3’s revenue miss, Voxzogo softness and greater acknowledgment of emerging competitive risks, even though they continue to view the shares as undervalued. Analyst Commentary Analyst reactions to BioMarin’s Q3 update reflect a more nuanced view of the company’s medium term growth profile, with reduced price targets but largely constructive ratings as investors recalibrate for competitive dynamics and updated long range guidance.BMRN: Shares Will Strengthen As 2025 Guidance and Pipeline Progress Drive Upside
BioMarin Pharmaceutical's analyst price target has been reduced from $90.50 to $89.36. Analysts cite slightly lower growth and profit margin expectations, new competitive pressures, and revised long-term guidance as key drivers for the change.BMRN: Shares Will Recover As Revenue Guidance Aligns With Market Expectations
Analysts have modestly reduced their price target for BioMarin Pharmaceutical, trimming it by $0.10 to $90.50. Recent updates reflect a more cautious outlook on revenue growth and profit margins in light of evolving competitive and regulatory expectations.BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead
Analysts have lowered their average price target for BioMarin Pharmaceutical from about $94.80 to $90.60. This reflects a cautious view following revenue misses, reduced long-term guidance due to anticipated competition, and updated profit margin forecasts.Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts
Oct 30
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
BioMarin Pharmaceutical's analyst price target was revised slightly lower, decreasing from $95.16 to $94.80 per share as analysts weighed ongoing competitive risks to Voxzogo and modest changes to key financial assumptions. Analyst Commentary Recent analyst coverage of BioMarin Pharmaceutical reflects a mix of optimism and caution surrounding the company's future prospects, especially regarding its growth story, competitive landscape, and valuation relative to peers.Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
Analysts have slightly lowered their price target for BioMarin Pharmaceutical to $95.16. This adjustment reflects carefully balanced views on future revenue growth, competitive risks affecting key drugs, and the company's ongoing potential for pipeline advancement.Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 06Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Jul 22BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
Jan 23Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Nov 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Dec 31 2025 | US$22m | US$1m | US$349m |
| Sep 30 2025 | n/a | n/a | US$520m |
| Jun 30 2025 | n/a | n/a | US$657m |
| Mar 31 2025 | n/a | n/a | US$524m |
| Dec 31 2024 | US$15m | US$1m | US$427m |
| Sep 30 2024 | n/a | n/a | US$322m |
| Jun 30 2024 | n/a | n/a | US$257m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | US$19m | US$65k | US$168m |
Tazminat ve Piyasa: Alexander 'nin toplam tazminatı ($USD 21.93M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 14.54M ).
Tazminat ve Kazançlar: Alexander şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.
CEO
Alexander Hardy (56 yo)
2.4yrs
Görev süresi
US$21,927,563
Tazminat
Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023 having joined in December 2023. He had been Chief Executive Officer at Ge...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 2.4yrs | US$21.93m | 0.11% $ 11.6m | |
| CFO & Executive VP of Finance | 6.3yrs | US$6.83m | 0.064% $ 6.6m | |
| Executive VP & CTO | no data | US$5.69m | 0.044% $ 4.5m | |
| Executive VP & Chief Commercial Officer | 2yrs | US$5.71m | 0.0039% $ 408.4k | |
| Executive VP and Chief Research & Development Officer | 1.7yrs | US$7.17m | 0.029% $ 3.0m | |
| VP, Chief Accounting Officer & Principal Accounting Officer | less than a year | Veri yok | Veri yok | |
| Chief Scientific Officer & Senior VP of Research and Early Development | no data | Veri yok | Veri yok | |
| Executive Vice President | less than a year | Veri yok | Veri yok | |
| Executive VP | 22.3yrs | US$5.06m | 0.041% $ 4.2m | |
| Executive VP & Chief People Officer | 7.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Technical Development | 4.6yrs | Veri yok | Veri yok | |
| Executive VP | 2.3yrs | Veri yok | Veri yok |
2.4yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: BMRN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 2.4yrs | US$21.93m | 0.11% $ 11.6m | |
| Independent Chairman of the Board | 19.4yrs | US$570.04k | 0.062% $ 6.5m | |
| Independent Director | 2.4yrs | US$501.29k | 0.0011% $ 117.7k | |
| Independent Director | less than a year | US$451.23k | Veri yok | |
| Independent Director | 9.8yrs | US$509.04k | 0.014% $ 1.5m | |
| Independent Director | 1.3yrs | US$492.79k | 0.00022% $ 22.9k | |
| Independent Director | 5.3yrs | US$502.79k | 0.011% $ 1.2m | |
| Independent Director | 8.7yrs | US$509.54k | 0.016% $ 1.6m | |
| Independent Director | 2.4yrs | US$493.66k | 0.0011% $ 117.7k | |
| Independent Director | 6.8yrs | US$505.04k | 0.012% $ 1.2m | |
| Independent Director | 2.4yrs | US$487.04k | 0.0011% $ 117.7k |
2.4yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: BMRN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/01 16:04 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
BioMarin Pharmaceutical Inc. 48 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jack Allen | Baird |
| Ying Huang | Barclays |
| Eliana Merle | Barclays |